Clinical Trial Details

Trial ID: L0749
Source ID: IRCT20170206032417N4
Associated Drug: Garlic
Title: The effect of garlic powder supplementation on body composition, liver echogenicity, insulin resistance, liver enzymes, lipid profile and oxidative stress in patients with non alcoholic fatty liver disease
Acronym: --
Status: Recruiting
Study Results: No Results Available
Results: --
Conditions: non alcoholic fatty liver disease. <br>Fatty (change of) liver, not elsewhere classified;K76.0
Interventions: Intervention 1: Intervention group: The intervention group will be consume 4 tablets of 400 miligrams per day garlic in addition to usual treatment for three months. Intervention 2: Control group: The control group will be consume 4 tablets of 400 miligra
Outcome Measures: Weight. Timepoint: At weeks 0, 6, 12. Method of measurement: scale. kg.;Body mass index. Timepoint: At weeks 0, 6, 12. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.;Gamma Glutamyl transferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;ALP. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method , IU\ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Alanine Aminotransferase. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Fasting blood sugar. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, IU\ Lit.;Serum insulin. Timepoint: At weeks 0, 12. Method of measurement: Radioimmunoassay.;Body fat mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Skeletal muscle mass. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, kg.;Waist circumference. Timepoint: At weeks 0, 6, 12. Method of measurement: BIA, cm.;Hepatic steatosis. Timepoint: Before intervention and three month after intervention. Method of measurement: Ultrasonography.;HDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Triglyceride. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;LDL cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total cholesterol. Timepoint: At weeks 0, 6, 12. Method of measurement: Enzymatic method, mg/dl.;Total antioxidant capacity. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;SOD. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;MDA. Timepoint: At weeks 0, 12. Method of measurement: spectrophotometry, Nmol/l.;Systolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg.;Diastolic blood pressure. Timepoint: At weeks 0, 6, 12. Method of measurement: Mercury sphygmomanometer, mmHg.;FATTY LIVER INDEX. Timepoint: At weeks 0, 6, 12. Method of measurement: Formula.;Quantity of appetite. Timepoint: At weeks 0, 6, 12. Method of measurement: VAS questionnaire.;Intestinal function. Timepoint: At weeks 0, 6, 12. Method of measurement: Bristol stool questionaire.;HOMA-IR. Timepoint: At weeks 0, 12. Method of measurement: Formula.nan
Sponsor/Collaborators: Vice Chancellor for research of Urmia University of Medical Sciences
Gender: All
Age: 18 years75 years
Phases: Not applicable
Enrollment: 90
Study Type: interventional
Study Designs: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Non-Alcoholic Fatty liver patients referred to the gastroenterology clinic of Imam Khomeini Hospital of Urmia were sel
Start Date: 28/04/2019
Completion Date: --
Results First Posted: --
Last Update Posted: 21 May 2019
Locations: Iran (Islamic Republic of)
URL: http://en.irct.ir/trial/34737

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D147 Garlic Biological drug DB10532 -- -- Under clinical trials Details
D080 Citrulline Chemical drug DB00155 -- -- Under clinical trials Details
D083 CLA Chemical drug DB01211 KCNH2; SLCO1B1; SLCO1B3 -- Under clinical trials Details
D094 Cysteamine Chemical drug DB00847 GSS stimulant Renal drug Under clinical trials Details
D095 Cysteamine bitartrate Chemical drug DB00847 -- -- Under clinical trials Details
D182 Insulin Biological drug DB00030 INSR agonist; CPE modulator&product of -- Under clinical trials Details
D199 L-alanine Chemical drug DB00160 KYNU -- Failed in clinical trials Details
D316 S-adenosyl-L-methionine Chemical drug DB00118 GNMT cofactor Antiviral Under clinical trials Details
D328 Serine Chemical drug DB00133 SRR Improve insulin resistance Under clinical trials Details
D545 Pig placenta extract Biological extract -- -- -- Under clinical trials Details